las-190792
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2013 (NCT02059434)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Dual acting MABA (beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists)
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Dual acting MABA (beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists)
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12- Mol. weight
- 811.38 g/mol
- Lipinski Ro5
- 4 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3916700 ↗
- ChEMBLCHEMBL3545272 ↗
Also known as
- las190792
- las190792
- las-190792
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02059434 | Phase 1 | Sep 1, 2013 | AstraZeneca |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1